GlassScriptPhysician profile
Mandy Lee Ramani
NPI 1497750640
$7,073.95
in general payments reported to CMS, 2019-2025
38 companies · $1,255 in 2025
The $1,255 reported for 2025 was more than what 78% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $462 · 2021: $889 · 2022: $1,254 · 2023: $1,144 · 2024: $1,339 · 2025: $1,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,737.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,959.44 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $921.96 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $874.49 | 2020-2025 | Dupixent, Libtayo |
| Abbvie INC. | $565.77 | 2021-2025 | |
| Lilly USA, LLC | $383.72 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $297.42 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $275.22 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $201.29 | 2019-2025 | |
| Leo Pharma INC. | $190.10 | 2019-2025 | Anzupgo, Adbry |
| Amgen INC. | $163.03 | 2021-2025 | Otezla |
| Incyte Corporation | $131.24 | 2021-2025 | Opzelura |
| Allergan, INC. | $126.05 | 2019-2021 | |
| Epi Health, LLC | $116.16 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $94.84 | 2020-2021 | |
| Almirall LLC | $78.74 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $71.79 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $64.59 | 2024-2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.27 | 2019 | |
| Janssen Biotech, INC. | $48.04 | 2020-2022 | |
| Biofrontera INC. | $46.92 | 2019-2020 | |
| Pierre Fabre Pharmaceuticals, INC. | $39.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.01 | 2020 | |
| Dusa Pharmaceuticals, INC. | $35.90 | 2019 | |
| Krystal Biotech INC | $30.01 | 2024 | Vyjuvek |
| E.R. Squibb & Sons, L.L.C. | $29.14 | 2025 | Sotyktu |
| Chiesi USA, INC. | $28.83 | 2025 | Filsuvez |
| Dermira, INC. | $26.41 | 2019 | |
| Botanix Sb INC | $21.03 | 2025 | Sofdra |
| Organon LLC | $20.05 | 2025 | Vtama |
| Ucb, INC. | $17.83 | 2021 | |
| Sebela Pharmaceuticals INC. | $16.81 | 2022 | |
| Lnhc, INC | $16.56 | 2025 | Zelsuvmi |
| Phadia US INC. | $16.16 | 2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2022 | |
| Icad, INC | $15.77 | 2022 | |
| Sandoz INC. | $15.21 | 2020 | |
| Aclaris Therapeutics, INC. | $13.55 | 2019 | |
| Journey Medical Corporation | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Ramani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.